Belatacept based immunosuppression: What and when to combine?

Area of Science:

• Nephrology
• Immunosuppression
• Transplant Medicine

Background:

• Kidney transplant recipients often require salvage immunosuppression regimens.
• Belatacept is an option for maintenance immunosuppression.
• Evaluating belatacept-based salvage regimens is crucial for optimizing transplant outcomes.

Purpose of the Study:

• To examine the impact of belatacept-based salvage immunosuppression on kidney transplant outcomes.
• To compare outcomes across different belatacept-based salvage regimens.
• To assess the safety and efficacy of belatacept in salvage therapy.

Main Methods:

• Single-center retrospective study of adult kidney transplant recipients (2011-2022).
• Patients converted to belatacept salvage therapy.
• Collected data included eGFR, graft survival, infection/neoplasia incidence, histology, and donor-specific antibody (DSA).

Main Results:

• Three groups: MMF/Bela (n=28), CNI/Bela (n=22), CNI/MMF/Bela (n=13).
• DSA decreased post-belatacept (15.67%, p=0.15).
• No significant differences in eGFR, graft survival, or incidence of death/allograft failure between groups.

Conclusions:

• Belatacept-based salvage regimens demonstrate comparable outcomes.
• eGFR, graft survival, infection/neoplasia rates, and DSA levels were similar across regimens.
• Supports the safety and efficacy of belatacept in diverse immunosuppression strategies.